Crisaborole’s safety holds up in long-term atopic dermatitis trial

SCOTTSDALE, ARIZ. – The phosphodiesterase-4 inhibitor crisaborole was well tolerated over 6 to 12 months, yielding no major safety signals during a multicenter, open-label extension study of patients with mild-to-moderate atopic dermatitis. These safety results held up across age groups and over...
Source: Skin and Allergy News - Category: Dermatology Source Type: news